TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02851511

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS (active stimulation)
Description: A Soterix Clinical Trials Direct Current Stimulator will apply 20 minutes of 2.0mA direct current through two biocarbon rubber electrodes encased in saline soaked 5cm x 7cm sponges (8cc of 0.9% saline solution per sponge) placed over the frontal cortices at F3 and F4 (10-20 system).
Study: NCT01963832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Study: NCT02851511

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS (active stimulation)
Description: A Soterix Clinical Trials Direct Current Stimulator will apply 20 minutes of 2.0mA direct current through two biocarbon rubber electrodes encased in saline soaked 5cm x 7cm sponges (8cc of 0.9% saline solution per sponge) placed over the frontal cortices at F3 and F4 (10-20 system).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS (sham stimulation)
Description: Sham stimulation is performed with the same device and all procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2 mA of direct current stimulation at the beginning of the session. Participants habituate to the sensation of tDCS within 30-60 seconds of stimulation. This procedure provides the same sensation of tDCS without the full duration of stimulation, making it a highly effective sham procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS (sham stimulation)
Description: Sham stimulation is performed with the same device and all procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2 mA of direct current stimulation at the beginning of the session. Participants habituate to the sensation of tDCS within 30-60 seconds of stimulation. This procedure provides the same sensation of tDCS without the full duration of stimulation, making it a highly effective sham procedure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Training
Description: Educational training involves watching educational videos produced by the National Geographic Channel, which cover a range of topics such as history, nature, and wildlife. Participants will be asked to complete questions on the content of the videos to ensure sustained attention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Training
Description: Educational training involves watching educational videos produced by the National Geographic Channel, which cover a range of topics such as history, nature, and wildlife. Participants will be asked to complete questions on the content of the videos to ensure sustained attention.
Study: NCT02029703

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Synvisc-One Injection

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Injection
Study: NCT03909464

Intervention type: DEVICE
Intervention: Neurosensory testing with Pressure-Specified Sensory Device
Description: Patients will have neurosensory function of hands and feet tested with the non-invasive Pressure-Specified Sensory Device.

Intervention type: DEVICE
Intervention: Neurosensory testing with Pressure-Specified Sensory Device
Description: Patients will have neurosensory function of hands and feet tested with the non-invasive Pressure-Specified Sensory Device.
Study: NCT03566589

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum PS128
Description: daily ingestion of 60 billion colony forming unit (CFU) of Lactobacillus plantarum PS128 (30 billion CFU/capsule)
Study: NCT04394819

Intervention type: OTHER
Intervention: electromyography-triggered electrical stimulation
Description: All treatments were planned as 2 sessions per week, for a total of 10 sessions for 5 weeks. For EMG-trigger-ES application, dual-channel Nu-Tek® brand, Maxi plus 2 Model EMG-trigger-BF-ES Device in our clinic was planned to be used. With EMG-triggered-ES application, while the patient is in a sitting position, shoulder adduction, and the elbow is 90 degrees of flexion and pronation, the patient will extend to the ball of 5 cm in diameter, which is placed as far as the distance between the acromion and the 3rd toe, and then the finger-wrist active extension will be stimulated and then It was planned to apply the ball to be grasped. One of the two 5x5 cm superficial square electrodes of the device was planned to be placed on the extensor carpi radialis and extensor digitorum Communis and the other 2 cm distal.
Study: NCT01954043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib 150 mg twice a day (BID)
Description: Dabrafenib dosed at 150mg twice a day from Day 1 to the morning of Day 29

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole 40 mg once daily (OD)
Description: Rabeprazole dosed at 40mg each morning on Days 16 to 19

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg OD
Description: Rifampin dosed at 600mg each morning on Days 20 to 29
Study: NCT03847168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN026
Description: Patient will be intravenously administrated with one dose of KN026 every week or every other week.
Study: NCT01285219

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pegylated filgrastim and ﬁlgrastim
Description: patients were administered pegylated filgrastim 100 ug/kg in cycle 1 and ﬁlgrastim 5 ug/kg/d in cycle 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ﬁlgrastim and pegylated filgrastim
Description: patients received ﬁlgrastim 5 ug/kg/d in cycle 1 and pegylated filgrastim 100 ug/kg in cycle 2
Study: NCT02056119

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrating Mesh Nebulizer Arm
Description: * Physician order received for subject, randomization to vibrating mesh nebulizer occurred.~* Aeroneb® Solo (Aerogen, Galway, Ireland) vibrating mesh nebulizer to be placed before the heater on the dry side of the heater water chamber on the inspiratory ventilator circuit.~* Aerosol treatment delivered per physician order.~* Mesh nebulizer to be replaced every 30 days per hospital protocol. a. Prior to every nebulizer change or every 3 days, study staff to be notified in order to obtain cultures.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jet Nebulizer Arm
Description: * Physician order received for subject, randomization to jet nebulizer occurred.~* Jet nebulizer, Misty Max 10™ (Carefusion, CA), placed into spring loaded t-piece between the humidifier and the ventilator (approximately 15 cm from the gas outlet).~* Aerosol treatment delivered per physician order at flow rates of 8-10 L/min.~* Jet nebulizer to be replaced every 3 days per hospital protocol. a. Prior to every nebulizer change or every 3 days, study staff to be notified in order to obtain cultures.
Study: NCT01348854

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iFS Femtosecond Laser System
Description: arcuate incisions placed with the iFS femtosecond laser

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iFS Femtosecond Laser System
Description: arcuate incisions placed with the iFS femtosecond laser
Study: NCT00865475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZT+3TC+ABV (Trizivir)
Description: Patients on treatment with TZV and viral suppression will be randomized to keep on TZV vs switching to LPV/r monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switching to LPV/r monotherapy (Kaletra)
Description: Patients on AZT+3TC+ABV with viral suppression will be randomized to keep on vs switching to LPV/r
Study: NCT02741011

Intervention type: OTHER
Group type: OTHER
Intervention: Radiological examination
Description: During the period of two years, mentally handicapped patients were enrolled in this study. First a radiological examination was performed under sedation anesthesia and then an oral examination was performed when patient underwent general anesthesia for dental treatments. Oral and radiological examinations were compared with each other and also with treatment results to define the necessity of the radiological examination of mentally handicapped patients.
Study: NCT02613780

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Crosslinking
Description: corneal collagen crosslinking with riboflavin

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Crosslinking
Description: corneal collagen crosslinking with riboflavin

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photorefractive keratectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photorefractive keratectomy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iDesign® Advanced WaveScan Studio
Description: Used to map wavefront aberration in planning photorefractive keratectomy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iDesign® Advanced WaveScan Studio
Description: Used to map wavefront aberration in planning photorefractive keratectomy
Study: NCT03818308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir and Velpatasvir
Description: All subjects will receive one film-coated tablet of sofosbuvir/velpatasvir (400/100 mg) orally once daily for 8 weeks.
Study: NCT03605017

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Executive Function Training (VREFT)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Executive Function Training (VREFT)
Study: NCT00498277

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging
Description: One MRI sequence done to look for relative fat, and a second extra MRI sequence done to look for the diffusion.
Study: NCT03614858

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-19/22
Description: Split intravenous infusion of CART-19/22 cells of (Dose escalating infusion of 1 - 20 x10\^6 CART-19/22 cells/kg).
Study: NCT04201951

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic acid injection
Description: Participant in group A will receive 2 ampules of 5 milliliters (mL) Tranexamic acid applied to 20 mL of 5% glucose water slowly intravenously immediately after the delivery of the fetus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid injection
Description: Participant in group A will receive 2 ampules of 5 milliliters (mL) Tranexamic acid applied to 20 mL of 5% glucose water slowly intravenously immediately after the delivery of the fetus

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Glucose water 5%
Description: Group B will receive 30 mL of 5% glucose water slowly intravenously immediately after the delivery of the fetus

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose water 5%
Description: Group B will receive 30 mL of 5% glucose water slowly intravenously immediately after the delivery of the fetus
Study: NCT01260662

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 1 mg/kg IV bolus followed by 0.5 mg/kg every 3 minutes as need for sedation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1:1 Propofol/Ketamine
Description: Propofol and ketamine mixed 1:1, given at 1 mg/kg IV bolus followed by 0.5 mg/kg every 3 minutes as need for sedation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4:1 Propofol/Ketamine
Description: Propofol and ketamine mixed 4:1, given at 1 mg/kg IV bolus followed by 0.5 mg/kg every 3 minutes as need for sedation
Study: NCT04219293

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microneedling w/ and w/o PRP
Description: i. Split face comparison. Vertical line drawn midline nose extending upwards to hairline and downwards to jawline separating face into two equal treatment areas. The patients determined side of face will be treated with SkinPen Microneedling and PRP the other (nondetermined from randomization) will be treated with SkinPen Microneedling and glide. The patient side of face that will not use PRP will be treated first. The following settings will be used as treatment protocol. Topical anesthetic Benzocaine 20%, Lidocaine 10%, and Tetracaine 10% will be applied covering entire treatment area. The anesthetic will remain on skin for 30 minutes.

Intervention type: DEVICE
Group type: OTHER
Intervention: Microneedling w/ and w/o PRP
Description: i. Split face comparison. Vertical line drawn midline nose extending upwards to hairline and downwards to jawline separating face into two equal treatment areas. The patients determined side of face will be treated with SkinPen Microneedling and PRP the other (nondetermined from randomization) will be treated with SkinPen Microneedling and glide. The patient side of face that will not use PRP will be treated first. The following settings will be used as treatment protocol. Topical anesthetic Benzocaine 20%, Lidocaine 10%, and Tetracaine 10% will be applied covering entire treatment area. The anesthetic will remain on skin for 30 minutes.
Study: NCT04157764

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HomeChoice Claria APD machine with SHARESOURCE
Description: HomeChoice Claria APD machine with SHARESOURCE software. SHARESOURCE is a software can telemonitor patients' compliance
Study: NCT03904082

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane block ( Group ı)
Description: ESP Block will perform preoperative to all patients in ESP block group. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus Anterior Plane block ( Group ıı)
Description: SAP Block will perform preoperative to all patients in SAP block group. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control Group (GROUPIII)
Description: Control group will receive no intervetion. Patients in all groups will provide with intravenous patient- controlled analgesia device containing morphine for postoperative analgesia.
Study: NCT04108689

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-ACT
Description: An internet-based behavioral psychotherapy intervention to enhance athletic performance in elite ice hockey players.
Study: NCT01455740

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Visit Incentive (PVI)
Description: All participants received the standard of care (SOC), which included not only medical care but also a wide range of social services. In addition, participants in the PVI arm received financial incentives designed to motivate health-improving behaviors. After the initial study enrollment visit, participants in the PVI arm received a $30 payment each time they showed up as scheduled for one of their next four HIV primary care visits.~Participants in the PVI arm were also asked to return for a sixth, unanticipated study visit approximately three months after the last of the four study visits to which the incentive scheme applied. To reduce attrition, participants were offered $100 for showing up to the fifth and sixth study visits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentive Choice (IC)
Description: All participants received the SOC. In addition, participants in the IC arm received financial incentives designed to motivate health-improving behaviors. At the initial study enrollment visit, participants in the IC arm chose between either the incentive scheme assigned to the PVI arm or an incentive scheme that tied payments to clinic attendance and ART medication adherence. Participants who selected the 2nd option received a $30 payment at each of their next 4 HIV primary care visits if the (i) showed up as scheduled and (ii) presented a dose-recording pill bottle cap indicating that they correctly took at least 90% of doses of a sentinal medication since the previous study visit.~Participants in the IC arm were also asked to return for a 6th, unanticipated study visit approximately three months after the last of the 4 study visits to which the incentive scheme applied. To reduce attrition, participants were offered $100 for showing up to the 5th and 6th study visits.
Study: NCT04100954

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reinforced prosthesis
Description: Implementation of a reinforced prosthesis during a medical consultation or under local anesthesia, after removal of the former prosthesis, in case of intraprothetic leakage.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard prosthesis
Description: Implementation of a standard prosthesis during a medical consultation or under local anesthesia, after removal of the former prosthesis, in case of intraprothetic leakage.
Study: NCT02958228

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Mental Imagery Training (PMIT)
Study: NCT01963832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Study: NCT02958228

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Control Training (CCT)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Study: NCT04323319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESWT, Graston Technique
Description: The treatment period for each group was determined as 4 weeks. Stretching program for each group will be given as home exercise program. Stretching exercises will be completed in 3 sets, 2 sets per day, stretching for 30 seconds.~Graston Technique Group will take treatment 2 times per week, ESWT group will take treatment 1 time per week.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESWT, Graston Technique
Description: The treatment period for each group was determined as 4 weeks. Stretching program for each group will be given as home exercise program. Stretching exercises will be completed in 3 sets, 2 sets per day, stretching for 30 seconds.~Graston Technique Group will take treatment 2 times per week, ESWT group will take treatment 1 time per week.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ESWT, Graston Technique
Description: The treatment period for each group was determined as 4 weeks. Stretching program for each group will be given as home exercise program. Stretching exercises will be completed in 3 sets, 2 sets per day, stretching for 30 seconds.~Graston Technique Group will take treatment 2 times per week, ESWT group will take treatment 1 time per week.
Study: NCT03458000

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PillCam UGI
Description: An esophageal capsule endoscope which is designed to visualize the upper gastrointestinal tract.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Patient was admitted to hospital for care and received in-patient EGD.
Study: NCT02890082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen stim in early follicular phase
Description: Day cycle of the patient when ovarian stimulation begin (early follicular phase) = D1 to D3~* Stimulation with simultaneously: TAM (tamoxifen) 60mg / day + FSH® 150 to 300 IU / day (following ovarian reserve)~* Monitoring (ultrasound + blood test E2, LH (luteinizing hormone) and P) every 2 to 3 days +/- dose adjustment of FSH~* Ovulation by blocking the GnRH antagonist (gonadotropin-releasing hormone : CETROTIDE) introduced according to the usual criteria,~* Continued monitoring (ultrasound + blood test E2, LH and P) every 2 to 3 days~* Triggering ovulation by OVITRELLE ® 250μg according to the usual criteria~* 35 h after the onset, oocyte puncture transvaginally the gynecology unit under local or general anesthesia.

Intervention type: DRUG
Group type: OTHER
Intervention: Tamoxifen stim in late follicular phase
Description: Day cycle of the patient when ovarian stimulation begin (late follicular phase) = D4 to D14~* Monitoring (ultrasound + blood test E2, LH and P) until a follicle of 15 mm~* Ovulation induction by OVITRELLE® 250μg.~* Continued monitoring (ultrasound + blood test E2, LH and P) 4 days after OVITRELLE® to the proper stage for the beginning of stimulation.~* Stimulation with simultaneously: TAM 60mg / day + FSH® 150 to 300 IU / day (following ovarian reserve) + CETROTIDE~* Continued monitoring (ultrasound + blood test E2, LH and P) every 2 to 3 days +/- adaptation of FSH~* Triggering ovulation by OVITRELLE ® 250μg according to the usual criteria~* 35 h after the onset, oocyte puncture transvaginally the gynecology unit under local or general anesthesia.

Intervention type: DRUG
Group type: OTHER
Intervention: Tamoxifen stim in luteal phase
Description: Day cycle of the patient when ovarian stimulation begin (luteal phase) = D15 to D28~* 1 or 2 Monitoring (ultrasound + blood test E2, LH and P) to check the validity of the post-ovulatory phase~* Stimulation with simultaneously: TAM 60mg / day + FSH® 150 to 300 IU / day (following ovarian reserve) + CETROTIDE~* Continued monitoring (ultrasound + blood test E2, LH and P) every 2 to 3 days +/- adaptation of FSH~* Triggering ovulation by OVITRELLE ® 250μg according to the usual criteria~* 35 h after the onset, oocyte puncture transvaginally the gynecology unit under local or general anesthesia
Study: NCT02524210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole and Dabigatran
Description: omeprazole 20 mg / day for 5 days, then the sixth day concomitant omeprazole 20 mg and 150 mg dabigatran etexilate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole and Dabigatran
Description: omeprazole 20 mg / day for 5 days, then the sixth day concomitant omeprazole 20 mg and 150 mg dabigatran etexilate
Study: NCT01653366

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Goal Setting
Description: Will include an initial physical therapy (PTA) consult to set exercise goals to increase physical activity by 6000 steps per week over the course of the trial, viewing of the Exercise and Breast Cancer digital video disc (DVD, followed by 10 regular phone calls or RN visits (weekly for the first month, then monthly) to follow up on whether or not those goals are being met and, if not, how best to meet them.
Study: NCT02524210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole and Dabigatran
Description: omeprazole 20 mg / day for 5 days, then the sixth day concomitant omeprazole 20 mg and 150 mg dabigatran etexilate
Study: NCT02829983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Use of 500mg of Clarithromycin twice a day for 3 days
Study: NCT01318083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin and glimepiride
Description: Alogliptin 12.5 mg, tablets, orally, once daily and glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily for up 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin and glimepiride
Description: Alogliptin 25 mg, tablets, orally, once daily and glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily for up 12 weeks.
Study: NCT02829983

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Use of placebo tablets twice a day for 3 days.